Terns Pharmaceuticals, Inc. (TERN) Tops Q2 EPS by 3c

Terns Pharmaceuticals, Inc. (NASDAQ: TERN) reported Q2 EPS of ($0.31), $0.03 better than the analyst estimate of ($0.34).

For earnings history and earnings-related data on Terns Pharmaceuticals, Inc. (TERN) click here.

You May Also Be Interested In

• Kalshi in early talks for IPO - The Information
• Huntington Ingalls wins $418M Navy contract
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals